Thromb Haemost 1981; 45(03): 255-256
DOI: 10.1055/s-0038-1650182
Original Article
Schattauer GmbH Stuttgart

Successful Treatment of Raynaud's Syndrome with Prostacyclin

Authors

  • J J F Belch

    1   The Department of Medicine, Southern General Hospital, Glasgow, U. K.
  • P Newman

    2   The Department of Clinical Physics and Bioengineering, West of Scotland Health Board, U. K.
  • J K Drury

    3   The Department of Vascular Surgery, Glasgow Royal Infirmary, Southern General Hospital, Glasgow, U. K.
  • H Capell

    1   The Department of Medicine, Southern General Hospital, Glasgow, U. K.
  • P Leiberman

    3   The Department of Vascular Surgery, Glasgow Royal Infirmary, Southern General Hospital, Glasgow, U. K.
  • W B James

    4   The Department of Radiology, Southern General Hospital, Glasgow, U. K.
  • C D Forbes

    1   The Department of Medicine, Southern General Hospital, Glasgow, U. K.
  • C R M Prentice

    1   The Department of Medicine, Southern General Hospital, Glasgow, U. K.
Weitere Informationen

Publikationsverlauf

Received 10. Februar 1981

Accepted 03. April 1981

Publikationsdatum:
06. Juli 2018 (online)

Preview

Summary

There is evidence to suggest that platelet activation occurs in Raynaud’s syndrome. We evaluated the effect of prostacyclin (PGI2) a potent antiplatelet and vasodilator agent in 5 female patients with Raynaud’s syndrome. Outpatient visits were made at weekly intervals for 4 weeks. At the first visit buffer solution (Wellcome Laboratories) was infused intravenously for 5 hrs, thereafter three five hr infusions of PGI2 at a peak dose of 10 ng/ Kg/min were given. Six weeks after the infusions patients were reviewed. Symptomatic improvement, including healing of ischaemic ulcers, occurred in 4 out of 5 patients. Thermography confirmed an increase in hand temperature after PCI2. Subjective and objective improvement has persisted for at least 6 weeks after the last treatment.